PACTR202401802272880尚未招募3 期
H-PRIME: Hydroxyurea - Pragmatic Reduction In Mortality and Economic burden
Imperial College0 个研究点目标入组 1,800 人开始时间: 2023年8月6日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 1,800
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 1 Month(s) 至 23 Month(s)(—)
- 性别
- All
入选标准
- •?Aged 1-10 years inclusive
- •?Confirmed SCD (either by HPLC or IEF at a qualified laboratory)
- •?Have received conjugate pneumococcal vaccination against Hib and S. pneumoniae (otherwise eligible but unvaccinated children will be vaccinated through the study as above)
- •?Carer willing/able to provide consent and to bring the child for follow-up visits, as demonstrated by either regular attendance at SCD clinics to date, or attending two visits (one of which may be the screening visit) before randomisation
排除标准
- •?Weighing <8kg – temporary exclusion pending the achievement of 8kg or more
- •?Already meet criteria for starting hydroxyurea in national guidelines (frequent crises (>5/year), known abnormal transcranial Doppler ultrasound velocities, stroke or acute chest syndrome)
- •?Already receiving hydroxyurea
- •?Taking concomitant medications that are contraindicated with any of the trial medications (hydroxyurea, SP, DHA-PQP, penicillin V, cotrimoxazole) (including, but not limited to, nefazodone, verapamil, rifampicin, isoniazid, ethambutol)
- •?A positive pregnancy test at screening or enrolment visits
- •?Known cancer
- •?A clinical history of previous or existing liver or renal diseases unrelated to sickle cell disease
- •?Known cardiac ventricular dysfunction or failure or a previous history of cardiac arrhythmias
- •?Known HIV (these children should receive cotrimoxazole prophylaxis and many will be receiving antiretrovirals that are contraindicated with one or more trial medications (zidovudine, amprenavir, atazanavir, indinavir, nelfinavir, ritonavir))
- •?Current participation in any other clinical trial of an investigational medicinal product
- •?Presence of acute infection on the day of screening (e.g. symptomatic P. falciparum malaria, pneumonia, septicaemia, meningitis, newly identified tuberculosis) – such children may be enrolled after recovery from an acute infection if they do not meet other exclusion criteria
研究者
相似试验
进行中(未招募)
3 期
H-PRIME: A clinical trial with three separate randomisations aimed at investigating the benefits of hydroxyurea, used pragmatically with only clinically-based monitoring, antimalarial prophylaxis with dihydroartemisinin-piperaquine and antibacterial prophylaxis with cotrimoxazole as potential improvements in the standard care of children living in Africa with sickle cell diseaseSickle cell diseaseCirculatory SystemISRCTN15724013Imperial College London1,800
尚未招募
不适用
Effects of tablet Hydroxyurea in Reduction of blood Transfusion Among Children Having babies with thalassemiaCTRI/2020/07/026938Prashant Bhimrao Agaldare
招募中
不适用
Evaluation of the efficacy of Hydroxyurea administration on blood oxygen saturation of COVID-19 patientsCOVID-19.COVID-19, virus identifiedU07.1IRCT20210901052358N2Shahid Beheshti University of Medical Sciences10
招募中
3 期
Investigating the efficacy and safety of Hydroxychloroquine nasal spray in controlling the symptoms of patients with COVID-19IRCT20080901001165N51Sina Darou Laboratories Company80
尚未招募
3 期
To Study the Potential role of drug Hyrdoxyurea in Thalassemia in reducing the burden of frequent blood transfusion in children of Southern RajasthaCTRI/2024/08/071925RNT Medical College
